LONDON – Sequana Medical NV has raised €19 million (US$21 million) in a private placing to fund continuation of the U.S. pivotal trial of its Alfapump in treating ascites due to cirrhosis of the liver and a European trial of the device in heart failure patients who have stopped responding to diuretics.

Liquid biopsy startup Elypta AB has raised €6.1 million (US$6.72 million) in a late seed financing led by Industrifonden and Sciety. Norrsken Foundation’s newly launched €100 million “impact-first” fund also contributed to the round. The Stockholm-based company plans to use the money to complete development of laboratory kits and software for measurement and analysis of a panel of metabolites it has identified.

The final scorecard for med-tech IPOs in 2019 shows that Lake Forest, Calif.-based Inmode Ltd. performed the best since its August debut, while San Diego-based Guardion Health Sciences Inc. lost the most stock value during the year.